Clinical Trial Search

Primary: Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at Day 28-30 — -1.0; -0.62; -2.2; -2.2 Percent of predicted FEV1 — p=0.076

Primary: Progression-free Survival (PFS) — 9.3; 10.1 Months

Primary: Alcohol Craving Rating in Response to Saline Infusion — 1.704; 1.766 Units on a scale

Primary: Change From Baseline in Participant Lean Body Mass — 1.26; 0.29 kg

Primary: Colonic Geometric Center at 24 Hours (GC24) — 3.1; 3.5; 2.2 units on a scale

Primary: Complete Response Rate (Complete Response and Complete Response Unconfirmed) Defined as Disappearance of All Evidence of Disease Based on Radiographic Findings on CT or…

Primary: the Difference Between the Time to Clot Formation in Seconds at Baseline and After Each Treatment — 0.0; 10.9; -6.5; 30.5 seconds — p=0.00

Primary: Total Pain Relief at 6 Hours Post Dose (TOTPAR 6) — 2.45; 4.37 units on a scale

Primary: Percentage Agreement Between Gadobutrol Perfusion Magnetic Resonance Imaging (MRI) (Blinded Reading) and SPECT (Central Reading) Regarding the Diagnosis for Detection of…

Primary: Change From Randomization in Montgomery and Asberg Depression Rating Scale (MADRS) — -12.5; -12.3 units on a scale

Primary: Forced Expiratory Volume (FEV1) Peak (0-3h) Response — 0.489; 0.556; 0.546; 0.602 Litre — p=0.0043

Primary: Number of Infants With Adverse Reactions After Vaccination — 22; 24; 17; 7 participants

Primary: Recommended Phase II Dose — 70; 800 mg

Primary: Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B…

Primary: The Area the Pterygium Enlarged or Regressed as Measured From the Limbus Before and After Subconjunctival Bevacizumab Injection. — 5.75 area in millimeters squared…